Skip to content
RKWD
ROCKWOOD RESEARCH · A CORPORATE FILINGS WEBSITE|STRAIGHT FROM THE SOURCE · SEC EDGAR|SPONSOREDYour message on this tape — bid on the Rockwood Ad Exchange · Rockwood Ad Exchange|
Rockwood Research
…

PVLA

PALVELLA THERAPEUTICS, INC.

Pharmaceutical Preparations · SIC 2834CIK 1583648Held by 6 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:XLINKEDINEMAIL
Revenue FY2025
—
Net Income FY2025
$(42.0M)
EPS (Basic, as reported)
$-3.71
Net Margin FY2025
—
ROE FY2025
-149.1%
Total Equity
$28.0M
Shares Out
14M
Business description

PALVELLA THERAPEUTICS, INC. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2013–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions
i
default rows · click any row to chart itRevenue: 6 → 43 +32.5% CAGR
Fiscal yearFY2016FY2017FY2018FY2019⚑FY2020FY2021FY2022FY2023⚑FY2024⚑FY2025
Revenue625274429312643——
Research & development(20)(22)(41)(55)(47)(67)(53)(42)(8)(23)
General & administrative(9)(18)(18)(18)(17)(17)(16)(17)(6)(16)
Total operating expenses(29)(40)(60)(73)(63)(83)(69)(73)(14)(39)
Operating income(23)(15)(31)(27)(34)(52)(43)(30)(14)(39)
Interest expense———————000
Other income (expense), net0(2)20(4)21011
Pre-tax income(23)(17)(27)(25)(37)(46)(33)(25)(17)(42)
Income tax expense0(1)00000000
Net income(23)(18)(27)(25)(37)(46)(33)(25)(17)(42)
EPS — basic————($0.68)($0.71)($0.45)($0.27)($7.83)($3.71)
EPS — diluted————($0.68)($0.71)—$2.17($7.83)($3.71)
Shares outstanding — basic (M)————54657490211
Shares outstanding — diluted (M)————5465—2211

Showing the latest 10 of 13 fiscal years.

  • ⚑ Weighted-average shares changed ×9.00 between FY2014 and FY2020 — likely a stock split. Per-share figures on either side are as reported and not adjusted.
  • ⚑ Weighted-average shares changed ÷50.00 between FY2023 and FY2024 — likely a reverse split. Per-share figures on either side are as reported and not adjusted.
  • ⚑ Weighted-average shares changed ×5.50 between FY2024 and FY2025 — likely a stock split. Per-share figures on either side are as reported and not adjusted.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.